Eupraxia Pharmaceuticals announced it will present clinical data from the Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis at Digestive Disease Week on May 2-5, 2026.
Key takeaways
Company will present 4 abstracts including an oral presentation on May 3, 2026, featuring 36-week histological improvement data from the RESOLVE trial.
Poster presentations on May 5, 2026, will cover endoscopic features, dysphagia durability, and dose determination for EP-104GI.
Management will host a virtual investor event on May 4, 2026, featuring KOLs discussing recurrent esophageal strictures and EP-104GI potential.
EP-104GI is a long-acting submucosal corticosteroid formulation injected into esophageal tissues, currently in Phase 1b/2 for EoE treatment.